At Debiopharm, every step we take is guided by one purpose: improving the lives of people affected by cancer and infectious diseases. As a privately-owned Swiss biopharmaceutical company, we’re driven by science, but above all, by the people behind every treatment — the patients and their families.
Through our unique “development only” model, we bring forward promising therapies and transform them into treatments that can reach those who need them most, faster.
Are you ready to bridge the gap between breakthrough science and commercial success?
We are currently looking for a dynamic Global Early Commercial Manager to shape the future of our oncology portfolio. In this pivotal role, you will be the commercial voice within Core Project Teams, driving the strategy for assets from preclinical stages through the start of Phase 3. Your mission is to maximize asset value and ensure our innovations meet the real-world needs of patients and providers. The role will be based at our Headquarters in Lausanne, Switzerland.
Location: Lausanne, Switzerland
Department: Business and Program Leadership & Management; Commercial Strategy
Contract: permanent role, full-time.
Executive Summary of Responsibilities
As the Global Early Commercial Manager, you are responsible for building and integrating marketing and commercial strategies into Debiopharm’s portfolio development plans. You will act as a strategic champion, transforming market insights into actionable product positioning, refining Target Product Profiles (TPP), and collaborating cross-functionally to ensure our oncology pipeline is competitively differentiated and ready for successful out-licensing or launch.
Requirements
Key Tasks & Responsibilities
Profile Required
Benefits
What we Offer
· Being part of a company where innovation, collaboration, and impact aren’t just values — they’re how we work every day
· Partner with teams across disciplines, at the forefront of oncology and anti-infective development
· An inclusive and respectful workplace — proud to be Equal-Pay certified
· Grow in a culture that values people, purpose, and performance
· A chance to grow, share, and shape the future of healthcare
What to Expect in the Recruitment Process
If your application is selected, you’ll be invited to interviews with Talent Acquisition and the Hiring Manager via Teams, followed by a panel interview and reference checks. Communication is handled via Workable—check your spam folder for emails from *@outbound.workable.com
Please contact our HR Department prior to submitting any profiles. We cannot accept unsolicited applications from agencies or recruiters.
Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe.
Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections.
Debiopharm completed the development and has licensed out 2 compounds: - Triptorelin, the active substance of Decapeptyl®/Trelstar®/Pamorelin®/Triptodur® 1, 3 and 6-month formulation and Moapar®/Salcacyl® -Oxaliplatin, the active substance of the branded Eloxatin®/Elplat®/Dacotin®/Dacplat®
If your university or biotech start-up has interesting molecules in early-stage research and you’re seeking a competent and committed partner to develop them further, please contact us!
